HK1252940A1 - 用於治療無效性紅細胞生成的方法和組合物 - Google Patents

用於治療無效性紅細胞生成的方法和組合物

Info

Publication number: HK1252940A1
Authority: HK; Hong Kong
Prior art keywords: compositions; methods; ineffective erythropoiesis; treating ineffective; treating
Prior art date: 2011-10-17

Application number

HK18112295.7A

Other languages

English (en)

Inventor

Seehra Jasbir

Scott Pearsall Robert

Kumar Ravindra

Venkata Sai Rajasekhar Suragani Naga

Original Assignee

Acceleron Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-17

Filing date

2018-09-26

Publication date

2019-06-06

2018-09-26 Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc

2019-06-06 Publication of HK1252940A1 publication Critical patent/HK1252940A1/zh

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Endocrinology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

HK18112295.7A 2011-10-17 2018-09-26 用於治療無效性紅細胞生成的方法和組合物 HK1252940A1 (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161547932P	2011-10-17	2011-10-17

Publications (1)

Publication Number	Publication Date
HK1252940A1 true HK1252940A1 (zh)	2019-06-06

Family

ID=48141315

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
HK15104178.9A HK1203413A1 (zh)	2011-10-17	2015-04-30	用於治療無效性紅細胞生成的方法和組合物
HK18109792.1A HK1250341A1 (zh)	2011-10-17	2018-07-30	用於治療無效性紅細胞生成的方法和組合物
HK18112295.7A HK1252940A1 (zh)	2011-10-17	2018-09-26	用於治療無效性紅細胞生成的方法和組合物

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
HK15104178.9A HK1203413A1 (zh)	2011-10-17	2015-04-30	用於治療無效性紅細胞生成的方法和組合物
HK18109792.1A HK1250341A1 (zh)	2011-10-17	2018-07-30	用於治療無效性紅細胞生成的方法和組合物

Country Status (13)

Country	Link
US (4)	US20130243743A1 (zh)
EP (3)	EP2797620B1 (zh)
JP (4)	JP6092883B2 (zh)
KR (4)	KR102079482B1 (zh)
CN (3)	CN107837390A (zh)
AU (4)	AU2012326207B2 (zh)
BR (3)	BR122019023166B1 (zh)
CA (1)	CA2852683A1 (zh)
DK (1)	DK3520805T3 (zh)
EA (2)	EA034563B1 (zh)
ES (2)	ES2869168T3 (zh)
HK (3)	HK1203413A1 (zh)
WO (1)	WO2013059347A1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1771470B1 (en)	2004-07-23	2013-06-26	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko)	2005-11-23	2019-01-16	악셀레론 파마 인코포레이티드	액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en)	2007-02-01	2013-04-10	Acceleron Pharma, Inc.	Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI548647B (zh)	2007-02-02	2016-09-11	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2120999B1 (en)	2007-02-09	2012-08-29	Acceleron Pharma, Inc.	Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma
CN103877564A (zh)	2007-09-18	2014-06-25	阿塞勒隆制药公司	活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt)	2008-08-14	2023-06-26	Acceleron Pharma Inc.	Gdf gaudyklės
BRPI1010587A2 (pt)	2009-06-08	2019-04-09	Acceleron Pharma Inc.	métodos para aumentar adipócitos termogênicos
EP2440577A4 (en)	2009-06-12	2013-01-23	Acceleron Pharma Inc	SHORTEN ACTRIIB FC FUSION PROTEINS
US20110070233A1 (en) *	2009-09-09	2011-03-24	Acceleron Pharma Inc.	Actriib antagonists and dosing and uses thereof
US8710016B2 (en)	2009-11-17	2014-04-29	Acceleron Pharma, Inc.	ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (ja)	2010-11-08	2014-01-30	アクセルロンファーマ，インコーポレイテッド	Ａｃｔｒｉｉａ結合剤およびその使用
US9925221B2 (en)	2011-09-09	2018-03-27	Celularity, Inc.	Treatment of amyotrophic lateral sclerosis using placental stem cells
MX366336B (es)	2012-11-02	2019-07-05	Celgene Corp	Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
KR102520970B1 (ko) *	2014-03-21	2023-04-12	악셀레론 파마 인코포레이티드	액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
BR112016024319B1 (pt) *	2014-04-18	2024-01-23	Acceleron Pharma Inc	USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
BR122023023170A2 (pt)	2014-06-13	2024-02-20	Acceleron Pharma Inc.	Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
MA41052A (fr)	2014-10-09	2017-08-15	Celgene Corp	Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) *	2014-12-03	2017-10-10	Acceleron Pharma Inc	Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
AU2015358469B2 (en) *	2014-12-03	2021-05-27	Acceleron Pharma Inc.	Activin-ActRII antagonists and uses for treating anemia
EP3878857A1 (en)	2015-04-22	2021-09-15	Biogen MA Inc.	Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
MY189601A (en) *	2015-05-13	2022-02-18	Celgene Corp	Treatment of beta-thalassemia using actrii ligand traps
WO2016187378A1 (en) *	2015-05-20	2016-11-24	Celgene Corporation	In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
WO2017079591A2 (en) *	2015-11-04	2017-05-11	Acceleron Pharma Inc.	Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CA3005975A1 (en)	2015-11-23	2017-06-01	Acceleron Pharma Inc.	Methods for treating eye disorders
AU2017338916B2 (en) *	2016-10-05	2022-03-24	Acceleron Pharma Inc.	Variant ActRIIB proteins and uses thereof
EP3538128A4 (en)	2016-11-10	2020-07-22	Keros Therapeutics, Inc.	ACTIVIN TYPE IIA RECEPTOR VARIANTS AND THEIR METHODS OF USE
CN111050770A (zh) *	2017-06-14	2020-04-21	细胞基因公司	治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法
CA3082146A1 (en)	2017-11-09	2019-05-16	Keros Therapeutics, Inc.	Activin receptor type iia variants and methods of use thereof
CA3087008A1 (en)	2018-01-12	2019-07-18	Keros Therapeutics, Inc.	Activin receptor type iib variants and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1265208A (en)	1915-09-07	1918-05-07	Edward C Kahn	Liquid-fuel burner.
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en)	1989-02-03	1990-08-09	Genetics Institute, Inc.	Erythropoietin receptor
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
US5677196A (en)	1993-05-18	1997-10-14	University Of Utah Research Foundation	Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en)	1994-03-29	1996-06-11	Onyx Pharmaceuticals, Inc.	Reverse two-hybrid method
US5885574A (en)	1994-07-26	1999-03-23	Amgen Inc.	Antibodies which activate an erythropoietin receptor
US5814565A (en)	1995-02-23	1998-09-29	University Of Utah Research Foundation	Integrated optic waveguide immunosensor
JPH11502717A (ja)	1995-04-11	1999-03-09	ザジェネラルホスピタルコーポレーション	逆ツーハイブリッドシステム
US5807839A (en) *	1997-04-15	1998-09-15	Advanced Viral Research Corp.	Method for stimulating red blood cell production
AU772694B2 (en)	1999-01-21	2004-05-06	Metamorphix International, Inc.	Growth differentiation factor inhibitors and uses therefor
BR0315316A (pt) *	2002-10-15	2005-08-16	Celgene Corp	Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
EP1771470B1 (en)	2004-07-23	2013-06-26	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
US8067562B2 (en)	2005-11-01	2011-11-29	Amgen Inc.	Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) *	2006-12-18	2010-02-04	Acceleron Pharma Inc.	Antagonists of actriib and uses for increasing red blood cell levels
TWI548647B (zh)	2007-02-02	2016-09-11	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
LT3750552T (lt) *	2008-08-14	2023-06-26	Acceleron Pharma Inc.	Gdf gaudyklės
US8216997B2 (en) *	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
RU2642302C1 (ru) *	2009-08-13	2018-01-24	Акселерон Фарма Инк.	Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов

2012
- 2012-10-17 BR BR122019023166-4A patent/BR122019023166B1/pt active IP Right Grant
- 2012-10-17 KR KR1020197025484A patent/KR102079482B1/ko active IP Right Grant
- 2012-10-17 EA EA201490809A patent/EA034563B1/ru not_active IP Right Cessation
- 2012-10-17 BR BR112014009528-0A patent/BR112014009528B1/pt active IP Right Grant
- 2012-10-17 ES ES19161424T patent/ES2869168T3/es active Active
- 2012-10-17 EP EP12842601.2A patent/EP2797620B1/en active Active
- 2012-10-17 CN CN201711069431.3A patent/CN107837390A/zh active Pending
- 2012-10-17 BR BR122019023174-5A patent/BR122019023174B1/pt active IP Right Grant
- 2012-10-17 CN CN201711069457.8A patent/CN107693776A/zh active Pending
- 2012-10-17 JP JP2014537186A patent/JP6092883B2/ja active Active
- 2012-10-17 CA CA2852683A patent/CA2852683A1/en active Pending
- 2012-10-17 US US13/654,191 patent/US20130243743A1/en not_active Abandoned
- 2012-10-17 EP EP19161424.7A patent/EP3520805B1/en active Active
- 2012-10-17 CN CN201280061672.2A patent/CN103987403B/zh active Active
- 2012-10-17 EA EA202090053A patent/EA202090053A3/ru unknown
- 2012-10-17 KR KR1020147013325A patent/KR20140084211A/ko not_active Application Discontinuation
- 2012-10-17 KR KR1020207004201A patent/KR20200019261A/ko not_active IP Right Cessation
- 2012-10-17 EP EP21153891.3A patent/EP3875104A1/en active Pending
- 2012-10-17 ES ES12842601T patent/ES2741477T3/es active Active
- 2012-10-17 DK DK19161424.7T patent/DK3520805T3/da active
- 2012-10-17 AU AU2012326207A patent/AU2012326207B2/en active Active
- 2012-10-17 KR KR1020227017193A patent/KR20220075438A/ko not_active Application Discontinuation
- 2012-10-17 WO PCT/US2012/060650 patent/WO2013059347A1/en active Application Filing
2015
- 2015-04-30 HK HK15104178.9A patent/HK1203413A1/zh unknown
2017
- 2017-01-23 US US15/413,184 patent/US20170137791A1/en not_active Abandoned
- 2017-02-09 JP JP2017022176A patent/JP6383821B2/ja active Active
- 2017-03-08 AU AU2017201580A patent/AU2017201580B2/en active Active
- 2017-07-28 US US15/663,361 patent/US20170327800A1/en not_active Abandoned
2018
- 2018-07-30 HK HK18109792.1A patent/HK1250341A1/zh unknown
- 2018-08-06 JP JP2018147507A patent/JP6796626B2/ja active Active
- 2018-09-26 HK HK18112295.7A patent/HK1252940A1/zh unknown
- 2018-10-11 AU AU2018247262A patent/AU2018247262B2/en active Active
2020
- 2020-08-07 US US16/987,756 patent/US20210207107A1/en active Pending
- 2020-08-24 JP JP2020140889A patent/JP2020186277A/ja active Pending
- 2020-12-09 AU AU2020286229A patent/AU2020286229A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK3520805T3 (da)	2021-04-19
BR122019023174B1 (pt)	2021-02-23
KR20220075438A (ko)	2022-06-08
AU2018247262B2 (en)	2020-12-24
JP2020186277A (ja)	2020-11-19
BR122019023166B1 (pt)	2021-02-23
CN103987403A (zh)	2014-08-13
AU2017201580A1 (en)	2017-03-30
EP2797620B1 (en)	2019-04-24
JP6092883B2 (ja)	2017-03-08
BR112014009528A8 (pt)	2019-12-10
EA202090053A2 (ru)	2020-04-30
JP2018165287A (ja)	2018-10-25
ES2869168T3 (es)	2021-10-25
KR20200019261A (ko)	2020-02-21
AU2017201580B2 (en)	2018-07-12
US20130243743A1 (en)	2013-09-19
JP6796626B2 (ja)	2020-12-09
US20170327800A1 (en)	2017-11-16
US20210207107A1 (en)	2021-07-08
HK1250341A1 (zh)	2018-12-14
KR20190105113A (ko)	2019-09-11
KR102079482B1 (ko)	2020-02-19
EP3520805A1 (en)	2019-08-07
WO2013059347A1 (en)	2013-04-25
EA202090053A3 (ru)	2020-06-30
BR112014009528A2 (pt)	2017-05-09
CN107693776A (zh)	2018-02-16
JP2014530253A (ja)	2014-11-17
KR20140084211A (ko)	2014-07-04
EP3875104A1 (en)	2021-09-08
ES2741477T3 (es)	2020-02-11
CN107837390A (zh)	2018-03-27
AU2020286229A1 (en)	2021-01-07
CN103987403B (zh)	2017-12-01
EP2797620A1 (en)	2014-11-05
CA2852683A1 (en)	2013-04-25
AU2018247262A1 (en)	2018-11-01
BR112014009528B1 (pt)	2020-12-29
EP3520805B1 (en)	2021-03-10
EA034563B1 (ru)	2020-02-20
EA201490809A1 (ru)	2014-09-30
HK1203413A1 (zh)	2015-10-30
JP2017101060A (ja)	2017-06-08
US20170137791A1 (en)	2017-05-18
AU2012326207A1 (en)	2014-05-15
AU2012326207B2 (en)	2016-12-15
JP6383821B2 (ja)	2018-08-29
EP2797620A4 (en)	2015-05-20

Publication	Publication Date	Title
HK1252940A1 (zh)	2019-06-06	用於治療無效性紅細胞生成的方法和組合物
HK1214521A1 (zh)	2016-07-29	用於治療蛋白質病的組合物和方法
HK1201475A1 (zh)	2015-09-04	治療疼痛的方法和組合物
IL227429A0 (en)	2013-09-30	The components and methods of cancer treatment
EP2755482A4 (en)	2015-03-25	COMPOSITIONS AND METHODS OF TREATING CANCER
EP2684167A4 (en)	2014-10-15	COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES
ZA201404187B (en)	2019-10-30	Compositions and methods for treating dental conditions
EP2771341A4 (en)	2015-09-23	NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
HK1190936A1 (zh)	2014-07-18	治療代謝綜合徵的方法和配方
DK3292875T3 (en)	2020-08-03	Compositions and methods for treating diseases
EP2766009A4 (en)	2015-05-20	METHOD AND COMPOSITIONS FOR SKIN TREATMENT
EP2800579A4 (en)	2015-08-19	METHODS AND COMPOSITIONS FOR THE TREATMENT OF DIABETES
HRP20180687T1 (hr)	2018-06-15	Kompozicije i metode za liječenje celijakije spru
EP2590674A4 (en)	2014-09-10	COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
IL232648A0 (en)	2014-06-30	Preparations and methods for treating glioma
HK1208598A1 (zh)	2016-03-11	治療疼痛的方法及組合物
IL229231A0 (en)	2014-01-30	Preparations and methods for the treatment of cancer
EP2723346A4 (en)	2015-03-18	COMPOSITIONS AND METHODS USEFUL FOR TREATING PEDICULOSIS
ZA201308683B (en)	2015-05-27	Methods and compositions suitable for preventing and treating hyperleptinemia
EP2714082A4 (en)	2015-01-14	COMPOSITIONS AND METHODS FOR TREATING PAIN
EP2718427A4 (en)	2014-12-24	COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLIOBLASTOMES
EP2800763A4 (en)	2015-11-11	COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
GB201122124D0 (en)	2012-02-01	Compositions and methods for treating biofilms
GB201104584D0 (en)	2011-05-04	Compositions and methods for treating biofilms